Madrigal Pharmaceuticals has a first mover advantage in the huge MASH market due to the approval of Rezdiffra. Read whether I ...

Since its historic FDA approval in March 2024 as the first medication for the treatment of the prevalent liver disease ...

Once-monthly efimosfermin alfa prescribed for metabolic dysfunction–associated steatohepatitis with F2 and F3 fibrosis ...

Q1 2025 Management View CEO Bill Sibold highlighted the momentum of Rezdiffra’s US launch, reporting $137 million in net sales for Q1 2025, reflecting a 33% increase quarter-over-quarter despite ...

We recently published an article titled Billionaire Nicholas J. Pritzker’s 8 Stocks with Huge Upside Potential. In this ...

Semaglutide and similar GLP-1 drugs are poised to become frontline treatments for a severe form of liver disease.

A large trial showed that the weight-loss drug could reduce liver inflammation and scarring caused by a common condition.

In a new study, Ozempic - a drug sold to help with obesity and diabetes - is attributed to helping this disease.

Rezdiffra sales reached $137 million for the quarter, beating consensus analyst estimates by more than $20 million and ...

Madrigal Pharmaceuticals Inc (MDGL) reports a 33% increase in net sales and significant patient growth, while navigating ...

First-quarter 2025 Rezdiffra™ (resmetirom) net sales of $137.3 million As of March 31, 2025, more than 17,000 patients on Rezdiffra Two-year compensated MASH cirrhosis (F4c) data from MAESTRO ...

CEO Bill Sibold highlighted the momentum of Rezdiffra’s US launch, reporting $137 million in net sales for Q1 2025, reflecting a 33% increase quarter-over-quarter despite typical Q1 industry ...